IntraTherapeutics IntraCoil PMA Foiled By Widespread Off-Label Stenting
This article was originally published in The Gray Sheet
Executive Summary
Sulzer/IntraTherapeutics said it will continue efforts to win FDA approval of its IntraCoil stent for use in the popliteal and femoral arteries, despite the rampant off-label use of other stents for the indication.
You may also be interested in...
FDA Rounds Up Biliary Stent Makers On Off-label Promotion
FDA gathered biliary stent manufacturers to discuss how to prevent off-label marketing for peripheral vascular disease while it clarifies the regulatory pathway for vascular stents
FDA Rounds Up Biliary Stent Makers On Off-label Promotion
FDA gathered biliary stent manufacturers to discuss how to prevent off-label marketing for peripheral vascular disease while it clarifies the regulatory pathway for vascular stents
FDA Defers To Expert Panel For Peripheral DES Guidance Development
Expert group consensus guidelines for preclinical studies and evaluation of peripheral drug-eluting stents will be available for public comment by early March